董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Myron Kaplan | 男 | Director and Chairman of the Board | 78 | 19.00万美元 | 未持股 | 2023-10-15 |
| Greg Duncan | 男 | Director | 58 | 13.20万美元 | 未持股 | 2023-10-15 |
| Joseph Todisco | 男 | Director and Chief Executive Officer | 47 | 269.12万美元 | 未持股 | 2023-10-15 |
| Janet M. Dillione | 女 | Director | 64 | 13.80万美元 | 未持股 | 2023-10-15 |
| Alan W. Dunton | 男 | Director | 69 | 14.20万美元 | 未持股 | 2023-10-15 |
| Steven W. Lefkowitz | 男 | Director | 67 | 15.30万美元 | 未持股 | 2023-10-15 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Phoebe Mounts | 女 | Executive Vice President and General Counsel and Head of Regulatory, Compliance and Legal | 73 | 101.05万美元 | 未持股 | 2023-10-15 |
| Matthew David | 男 | Chief Financial Officer | 46 | 113.65万美元 | 未持股 | 2023-10-15 |
| Joseph Todisco | 男 | Director and Chief Executive Officer | 47 | 269.12万美元 | 未持股 | 2023-10-15 |
| Elizabeth Hurlburt | 女 | Executive Vice President and Head of Clinical Operations | 44 | 84.48万美元 | 未持股 | 2023-10-15 |
| Erin Mistry | 女 | Executive Vice President and Chief Commercial Officer | 41 | 未披露 | 未持股 | 2023-10-15 |
董事简历
中英对照 | 中文 | 英文- Myron Kaplan
-
Myron Kaplan2016年4月成为CorMedix的董事。他是Kleinberg、 Kaplan、 Wolff & Cohen（纽约市一般做法的律师事务所）的创始合伙人，在那里他曾经实践过公司法和证券法，长达四十多年。 2012年，Kaplan先生成为Lehman Brothers Plan Holding Trust的受托人。此前，他曾在SAirGroup Finance USA Inc.（SAirGroup的子公司，公开发行债务证券）、Trans World Airlines, Inc.和Kitty Hawk, Inc.的董事会成员。在他商业和公民职务中，Kaplan目前担任一些私营公司的董事局，并一直是活跃多年的受托人董事会，曼哈顿儿童博物馆和JBI国际（前身为美国的犹太盲文协会）的各董事委员会。Kaplan先生毕业于Columbia University，拥有Harvard Law School的法学博士学位。
Myron Kaplan,became a director of CorMedix in April 2016 and became Chairman of the Board in August 2017. He is a founding partner of Kleinberg, Kaplan, Wolff & Cohen, P.C., a New York City general practice law firm, where he has practiced corporate and securities law for more than fifty years. In 2012, Mr. Kaplan became a trustee of the Lehman Brothers Plan Holding Trust. Previously, he served as a member of the board of directors of SAirGroup Finance (USA) Inc., a subsidiary of SAirGroup that had publicly issued debt securities, Trans World Airlines, Inc. and Kitty Hawk, Inc. Among his business and civic involvements, Mr. Kaplan currently serves on the boards of directors of a number of private companies and has been active for many years on the boards of trustees and various board committees of The Children's Museum of Manhattan and JBI International (formerly The Jewish Braille Institute of America). Mr. Kaplan graduated from Columbia College and holds a Juris Doctor from Harvard Law School. - Myron Kaplan2016年4月成为CorMedix的董事。他是Kleinberg、 Kaplan、 Wolff & Cohen（纽约市一般做法的律师事务所）的创始合伙人，在那里他曾经实践过公司法和证券法，长达四十多年。 2012年，Kaplan先生成为Lehman Brothers Plan Holding Trust的受托人。此前，他曾在SAirGroup Finance USA Inc.（SAirGroup的子公司，公开发行债务证券）、Trans World Airlines, Inc.和Kitty Hawk, Inc.的董事会成员。在他商业和公民职务中，Kaplan目前担任一些私营公司的董事局，并一直是活跃多年的受托人董事会，曼哈顿儿童博物馆和JBI国际（前身为美国的犹太盲文协会）的各董事委员会。Kaplan先生毕业于Columbia University，拥有Harvard Law School的法学博士学位。
- Myron Kaplan,became a director of CorMedix in April 2016 and became Chairman of the Board in August 2017. He is a founding partner of Kleinberg, Kaplan, Wolff & Cohen, P.C., a New York City general practice law firm, where he has practiced corporate and securities law for more than fifty years. In 2012, Mr. Kaplan became a trustee of the Lehman Brothers Plan Holding Trust. Previously, he served as a member of the board of directors of SAirGroup Finance (USA) Inc., a subsidiary of SAirGroup that had publicly issued debt securities, Trans World Airlines, Inc. and Kitty Hawk, Inc. Among his business and civic involvements, Mr. Kaplan currently serves on the boards of directors of a number of private companies and has been active for many years on the boards of trustees and various board committees of The Children's Museum of Manhattan and JBI International (formerly The Jewish Braille Institute of America). Mr. Kaplan graduated from Columbia College and holds a Juris Doctor from Harvard Law School.
- Greg Duncan
-
Greg Duncan自2020年4月1日起担任我们的首席执行官，自2018年起担任董事。自2020年11月起，邓肯先生担任CorMedixInc.董事NYSE American:CRMD一家生物制药公司，专注于开发和商业化用于预防和治疗传染病和炎症性疾病的治疗产品。此前，邓肯先生于2014年1月至2020年3月担任CeltaxSys，Inc.的总裁兼首席执行官，他是一家私人持有的生物技术公司，专注于开发罕见疾病的抗炎药物，在那里他扩大了所需的资本，以建立组织能力来推进临床前和临床开发候选药物。加入CeltaxSys之前，Duncan从2007年到2013年担任Belgium Base UCB（一家专业制药实体，开发和商业化免疫和中枢神经系统疾病药物）执行委员会成员。加入UCB公司之前，他曾担任Pfizer公司的多种执行美国和国际职务（从1989年到2007年），包括Pfizer公司的拉丁美洲运营总裁兼营销高级副总裁。他的运营团队曾负责许多制药品牌的推出，包括Lipitor、Zoloft、Viagra、Celebrex、Aricept、Lyrica、Cimzia、Zithromax（ZPACK）、Diflucan、Sutent、Rebif和Vimpat。Duncan先生曾担任IMC、Biotie Therapeutics、美国精神病学基金会、Bio国际组织（BIO）、东南生物（Sebio and the Georgia Bio Industry Association Group）的董事。Greg持有佐治亚州亚特兰大Emory University工商管理硕士学位，以及纽约州奥尔巴尼State University of New York经济学学士学位。
Greg Duncan,has been a director of CorMedix since November 2020. Mr. Duncan currently serves as the Chairman and CEO of Virios Therapeutics, a clinical-stage biopharmaceutical company developing and commercializing innovative antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM), and has served since April 2020. From 2014 and prior to joining his current company, Mr. Duncan served as President and CEO of Celtaxsys, a privately held biotechnology company focused on cystic fibrosis and other rare, inflammatory diseases. Mr. Duncan has spent the majority of his career in senior leadership roles in commercial stage pharmaceutical companies. From 2007 to 2013, he served as a senior executive at UCB, including as President of its North America business, as well as an executive committee member. Prior to his roles with UCB, Mr. Duncan spent approximately 17 years at Pfizer where he gained significant experience across sales and marketing functions including serving as SVP of US Marketing and later as President of Pfizer's Latin America business from 2005 to 2007. Mr. Duncan received his undergraduate degree from the State University of New York, Albany, and earned an MBA degree from Emory University. - Greg Duncan自2020年4月1日起担任我们的首席执行官，自2018年起担任董事。自2020年11月起，邓肯先生担任CorMedixInc.董事NYSE American:CRMD一家生物制药公司，专注于开发和商业化用于预防和治疗传染病和炎症性疾病的治疗产品。此前，邓肯先生于2014年1月至2020年3月担任CeltaxSys，Inc.的总裁兼首席执行官，他是一家私人持有的生物技术公司，专注于开发罕见疾病的抗炎药物，在那里他扩大了所需的资本，以建立组织能力来推进临床前和临床开发候选药物。加入CeltaxSys之前，Duncan从2007年到2013年担任Belgium Base UCB（一家专业制药实体，开发和商业化免疫和中枢神经系统疾病药物）执行委员会成员。加入UCB公司之前，他曾担任Pfizer公司的多种执行美国和国际职务（从1989年到2007年），包括Pfizer公司的拉丁美洲运营总裁兼营销高级副总裁。他的运营团队曾负责许多制药品牌的推出，包括Lipitor、Zoloft、Viagra、Celebrex、Aricept、Lyrica、Cimzia、Zithromax（ZPACK）、Diflucan、Sutent、Rebif和Vimpat。Duncan先生曾担任IMC、Biotie Therapeutics、美国精神病学基金会、Bio国际组织（BIO）、东南生物（Sebio and the Georgia Bio Industry Association Group）的董事。Greg持有佐治亚州亚特兰大Emory University工商管理硕士学位，以及纽约州奥尔巴尼State University of New York经济学学士学位。
- Greg Duncan,has been a director of CorMedix since November 2020. Mr. Duncan currently serves as the Chairman and CEO of Virios Therapeutics, a clinical-stage biopharmaceutical company developing and commercializing innovative antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM), and has served since April 2020. From 2014 and prior to joining his current company, Mr. Duncan served as President and CEO of Celtaxsys, a privately held biotechnology company focused on cystic fibrosis and other rare, inflammatory diseases. Mr. Duncan has spent the majority of his career in senior leadership roles in commercial stage pharmaceutical companies. From 2007 to 2013, he served as a senior executive at UCB, including as President of its North America business, as well as an executive committee member. Prior to his roles with UCB, Mr. Duncan spent approximately 17 years at Pfizer where he gained significant experience across sales and marketing functions including serving as SVP of US Marketing and later as President of Pfizer's Latin America business from 2005 to 2007. Mr. Duncan received his undergraduate degree from the State University of New York, Albany, and earned an MBA degree from Emory University.
- Joseph Todisco
-
Joseph Todisco自2020年8月起担任专业执行副总裁兼首席商务官，此前自2018年5月起担任专业商业高级副总裁。Todisco先生于2011年加入Amneal，担任企业发展主管，并一直是执行合并的管理团队的组成部分，以及多个其他业务开发、许可和并购。除了在公司发展中的角色，Todisco先生还担任公司子公司Gemini Laboratories，LLC的管理监督责任，将其从一开始打造成一个高利润的专业制药平台，并监督Amneal’；S的所有国际商业运营（从2013年到2018年）。在加入Amneal之前，Todisco先生花了5年多的时间领导Ranbaxy’；的北美商业战略和业务发展，并在Par Pharmaceuticals担任各种领导职务。在制药行业工作之前，Todisco先生是Oppenheimer&Co.的投资银行家，也曾在Marsh&McLennan Companies的金融服务部门工作。Todisco先生拥有乔治敦大学的经济学学位和福特汉姆大学商学院的工商管理硕士学位。
Joseph Todisco,became a director of CorMedix in March 2022. Prior to joining CorMedix as Cormedix Inc. Chief Executive Officer, he was a senior executive at Amneal Pharmaceuticals, where for the past 11 years he has held various roles, most recently as Executive Vice President, Chief Commercial Officer where he was responsible for Amneal Specialty, a growing branded products business. During his tenure at Amneal, Mr. Todisco held roles overseeing corporate development and international operations, leading commercial teams in several international markets including the UK, Australia and Germany, as well as leading Amneal's merger integration with Impax Laboratories in 2018. He was previously Co-Founder and managing executive of Gemini Laboratories, a specialty pharmaceutical company focused on the sales and marketing for niche branded products in the US Market. Gemini Laboratories was established as an affiliate of Amneal Pharmaceuticals and was subsequently acquired by Amneal in 2018. Prior to joining Amneal, Mr. Todisco was Vice President, Business Development & Licensing at Ranbaxy, Inc. where he was responsible for developing and executing Ranbaxy's North American commercial business strategy. Prior to Ranbaxy, he held various roles at Par Pharmaceutical, and in his earlier career held positions at Oppenheimer & Company and Marsh & McLennan Companies. Mr. Todisco obtained his MBA in finance from Fordham Graduate School of Business and his BA in Economics from Georgetown University. - Joseph Todisco自2020年8月起担任专业执行副总裁兼首席商务官，此前自2018年5月起担任专业商业高级副总裁。Todisco先生于2011年加入Amneal，担任企业发展主管，并一直是执行合并的管理团队的组成部分，以及多个其他业务开发、许可和并购。除了在公司发展中的角色，Todisco先生还担任公司子公司Gemini Laboratories，LLC的管理监督责任，将其从一开始打造成一个高利润的专业制药平台，并监督Amneal’；S的所有国际商业运营（从2013年到2018年）。在加入Amneal之前，Todisco先生花了5年多的时间领导Ranbaxy’；的北美商业战略和业务发展，并在Par Pharmaceuticals担任各种领导职务。在制药行业工作之前，Todisco先生是Oppenheimer&Co.的投资银行家，也曾在Marsh&McLennan Companies的金融服务部门工作。Todisco先生拥有乔治敦大学的经济学学位和福特汉姆大学商学院的工商管理硕士学位。
- Joseph Todisco,became a director of CorMedix in March 2022. Prior to joining CorMedix as Cormedix Inc. Chief Executive Officer, he was a senior executive at Amneal Pharmaceuticals, where for the past 11 years he has held various roles, most recently as Executive Vice President, Chief Commercial Officer where he was responsible for Amneal Specialty, a growing branded products business. During his tenure at Amneal, Mr. Todisco held roles overseeing corporate development and international operations, leading commercial teams in several international markets including the UK, Australia and Germany, as well as leading Amneal's merger integration with Impax Laboratories in 2018. He was previously Co-Founder and managing executive of Gemini Laboratories, a specialty pharmaceutical company focused on the sales and marketing for niche branded products in the US Market. Gemini Laboratories was established as an affiliate of Amneal Pharmaceuticals and was subsequently acquired by Amneal in 2018. Prior to joining Amneal, Mr. Todisco was Vice President, Business Development & Licensing at Ranbaxy, Inc. where he was responsible for developing and executing Ranbaxy's North American commercial business strategy. Prior to Ranbaxy, he held various roles at Par Pharmaceutical, and in his earlier career held positions at Oppenheimer & Company and Marsh & McLennan Companies. Mr. Todisco obtained his MBA in finance from Fordham Graduate School of Business and his BA in Economics from Georgetown University.
- Janet M. Dillione
-
Janet M. Dillione在2010年4月加入公司，目前担任公司Healthcare Division的执行副总裁和总经理，她在2010年5月被任命为执行官。在加入公司前，Dillione女士在Siemens Medical Solutions担任一些高级管理职务，最后担任的职务是该公司所属国际健康护理信息技术部门的总裁和首席执行官。她从2000年6月到2010年4月任职于Siemens。
Janet M. Dillione,has been a director of CorMedix since August 2015. Since November 2020, Ms. Dillione has served as the Chief Executive Officer of Connect America, a nationally recognized leader in comprehensive telehealth and remote patient monitoring solutions. Prior to joining Connect America and starting in May 2014, she served as Chief Executive Officer of Bernoulli Enterprise, Inc., a real-time connected healthcare information technology company. Previously, she was at Nuance Communications, Inc., a leading provider of voice and language solutions for businesses and consumers around the world, having joined Nuance in April 2010 as Executive Vice President and General Manager of the Healthcare Division and serving as an executive officer from March 2010 until May 2014. From June 2000 to March 2010, Ms. Dillione held several senior level management positions at Siemens Medical Solutions, a global leader in medical imaging, laboratory diagnostics, and healthcare information technology, including President and CEO of the global healthcare IT division. Ms. Dillione currently serves as a director of Vizient, Inc., a private health care performance improvement company. Ms. Dillione received her B.A. from Brown University in 1981 and completed the Executive Program at The Wharton School of Business of the University of Pennsylvania in 1998. - Janet M. Dillione在2010年4月加入公司，目前担任公司Healthcare Division的执行副总裁和总经理，她在2010年5月被任命为执行官。在加入公司前，Dillione女士在Siemens Medical Solutions担任一些高级管理职务，最后担任的职务是该公司所属国际健康护理信息技术部门的总裁和首席执行官。她从2000年6月到2010年4月任职于Siemens。
- Janet M. Dillione,has been a director of CorMedix since August 2015. Since November 2020, Ms. Dillione has served as the Chief Executive Officer of Connect America, a nationally recognized leader in comprehensive telehealth and remote patient monitoring solutions. Prior to joining Connect America and starting in May 2014, she served as Chief Executive Officer of Bernoulli Enterprise, Inc., a real-time connected healthcare information technology company. Previously, she was at Nuance Communications, Inc., a leading provider of voice and language solutions for businesses and consumers around the world, having joined Nuance in April 2010 as Executive Vice President and General Manager of the Healthcare Division and serving as an executive officer from March 2010 until May 2014. From June 2000 to March 2010, Ms. Dillione held several senior level management positions at Siemens Medical Solutions, a global leader in medical imaging, laboratory diagnostics, and healthcare information technology, including President and CEO of the global healthcare IT division. Ms. Dillione currently serves as a director of Vizient, Inc., a private health care performance improvement company. Ms. Dillione received her B.A. from Brown University in 1981 and completed the Executive Program at The Wharton School of Business of the University of Pennsylvania in 1998.
- Alan W. Dunton
-
Alan W. Dunton，药学博士，自2006年10月起担任董事会成员，自2006年4月起担任咨询公司Danerius有限公司负责人，2007年1月到2009年3月，Dunton博士在Panacos Pharmaceuticals公司担任总裁兼首席执行官；2009年3月至2011年1月担任Panacos常务董事。Dunton博士是上市公司Oragenics和Palatin Technologies的董事会成员。在过去的5年里，他曾是被Reckitt Benckiser Group plc收购的上市公司Adams Respiratory Therapeutics、 MediciNova, Inc.以及前上市公司Panacos Pharmaceuticals，Inc. 的董事会成员。另外，他还曾是EpiCept公司董事长，2013年他将EpiCept公司与Immune Pharmaceuticals合并。目前他还是私人医药公司Sancilio & Company的董事。
Alan W. Dunton,has been a director of Palatin since June 2011. He founded Danerius, LLC, a biotechnology consulting company, in 2006. From November 2015 through March 2018, he was senior vice president of research, development, and regulatory affairs for Purdue Pharma L.P., with responsibilities for overall research strategy and development programs. From January 2007 to March 2009, Dr. Dunton served as president and chief executive officer of Panacos Pharmaceuticals Inc. and he served as a managing director of Panacos from March 2009 to January 2011. Dr. Dunton is currently a member of the board of directors of the publicly traded companies Recce Pharmaceuticals Ltd (ASX: RCE), CorMedix Inc. (NYSE: CRMD) and Oragenics, Inc. (NYSE: OGEN). He previously served on the board of directors of the publicly traded companies Targacept, Inc., EpiCept Corporation (as Non-Executive Chairman), Adams Respiratory Therapeutics, Inc. (acquired by Reckitt Benckiser Group plc), MediciNova, Inc. and Panacos Pharmaceuticals, Inc. Dr. Dunton has served as a director or executive officer of various pharmaceutical companies, and from 1994 to 2001, Dr. Dunton was a senior executive in various capacities in the Pharmaceuticals Group of Johnson & Johnson, including president and managing director of the Janssen Research Foundation, the primary global R&D organization for Johnson & Johnson. Dr. Dunton received his M.D. degree from New York University School of Medicine, where he completed his residency in internal medicine. He also was a Fellow in Clinical Pharmacology at the New York Hospital/Cornell University Medical Center. - Alan W. Dunton，药学博士，自2006年10月起担任董事会成员，自2006年4月起担任咨询公司Danerius有限公司负责人，2007年1月到2009年3月，Dunton博士在Panacos Pharmaceuticals公司担任总裁兼首席执行官；2009年3月至2011年1月担任Panacos常务董事。Dunton博士是上市公司Oragenics和Palatin Technologies的董事会成员。在过去的5年里，他曾是被Reckitt Benckiser Group plc收购的上市公司Adams Respiratory Therapeutics、 MediciNova, Inc.以及前上市公司Panacos Pharmaceuticals，Inc. 的董事会成员。另外，他还曾是EpiCept公司董事长，2013年他将EpiCept公司与Immune Pharmaceuticals合并。目前他还是私人医药公司Sancilio & Company的董事。
- Alan W. Dunton,has been a director of Palatin since June 2011. He founded Danerius, LLC, a biotechnology consulting company, in 2006. From November 2015 through March 2018, he was senior vice president of research, development, and regulatory affairs for Purdue Pharma L.P., with responsibilities for overall research strategy and development programs. From January 2007 to March 2009, Dr. Dunton served as president and chief executive officer of Panacos Pharmaceuticals Inc. and he served as a managing director of Panacos from March 2009 to January 2011. Dr. Dunton is currently a member of the board of directors of the publicly traded companies Recce Pharmaceuticals Ltd (ASX: RCE), CorMedix Inc. (NYSE: CRMD) and Oragenics, Inc. (NYSE: OGEN). He previously served on the board of directors of the publicly traded companies Targacept, Inc., EpiCept Corporation (as Non-Executive Chairman), Adams Respiratory Therapeutics, Inc. (acquired by Reckitt Benckiser Group plc), MediciNova, Inc. and Panacos Pharmaceuticals, Inc. Dr. Dunton has served as a director or executive officer of various pharmaceutical companies, and from 1994 to 2001, Dr. Dunton was a senior executive in various capacities in the Pharmaceuticals Group of Johnson & Johnson, including president and managing director of the Janssen Research Foundation, the primary global R&D organization for Johnson & Johnson. Dr. Dunton received his M.D. degree from New York University School of Medicine, where he completed his residency in internal medicine. He also was a Fellow in Clinical Pharmacology at the New York Hospital/Cornell University Medical Center.
- Steven W. Lefkowitz
-
Steven W. Lefkowitz，2011年8月起，他成为CorMedix董事；2011年8月至2013年8月，他担任审核委员会主席；2011年8月起，他是审核和补偿委员会成员；2013年8月，他成为候补首席财务官；1990年6月起，他在Wade Capital Corporation（财务顾问服务公司）担任总裁，还是Wade Capital Corporation创始人。他还是公共贸易公司和私营企业的董事。1996年起，他成为Franklin Credit Management Corporation（前Franklin Credit Holding Corporation，公共专业消费金融公司）董事；2001年起，他成为AIS, RE（私人持有的再保险公司）董事；2007年起，他成为MedConx（私营医疗设备连接器公司）董事会主席。他在1977年获得达特茅斯学院学士学位，在1985年获得哥伦比亚大学工商管理硕士学位。
Steven W. Lefkowitz,was a director of CorMedix from August 2011 to June 2016. He was reappointed to the Board in June 2017. He also served as Cormedix Inc. acting Chief Financial Officer from August 2013 to July 2014. Mr. Lefkowitz has been the President and Founder of Wade Capital Corporation, a financial advisory services company, since June 1990. Mr. Lefkowitz has been a director of both public and private companies. Mr. Lefkowitz received his A.B. from Dartmouth College in 1977 and his M.B.A. from Columbia University in 1985. - Steven W. Lefkowitz，2011年8月起，他成为CorMedix董事；2011年8月至2013年8月，他担任审核委员会主席；2011年8月起，他是审核和补偿委员会成员；2013年8月，他成为候补首席财务官；1990年6月起，他在Wade Capital Corporation（财务顾问服务公司）担任总裁，还是Wade Capital Corporation创始人。他还是公共贸易公司和私营企业的董事。1996年起，他成为Franklin Credit Management Corporation（前Franklin Credit Holding Corporation，公共专业消费金融公司）董事；2001年起，他成为AIS, RE（私人持有的再保险公司）董事；2007年起，他成为MedConx（私营医疗设备连接器公司）董事会主席。他在1977年获得达特茅斯学院学士学位，在1985年获得哥伦比亚大学工商管理硕士学位。
- Steven W. Lefkowitz,was a director of CorMedix from August 2011 to June 2016. He was reappointed to the Board in June 2017. He also served as Cormedix Inc. acting Chief Financial Officer from August 2013 to July 2014. Mr. Lefkowitz has been the President and Founder of Wade Capital Corporation, a financial advisory services company, since June 1990. Mr. Lefkowitz has been a director of both public and private companies. Mr. Lefkowitz received his A.B. from Dartmouth College in 1977 and his M.B.A. from Columbia University in 1985.
高管简历
中英对照 | 中文 | 英文- Phoebe Mounts
Phoebe Mounts于2019年5月成为我们的执行Vice President and General Counsel兼监管，合规和法律主管。任职我们之前，她曾担任Morgan，Lewis&Bockius公司的合伙人，在那里她曾担任生命科学公司的法律顾问20年以上。作为她在Morgan Lewis工作的一部分，Mounts博士自2013年以来一直作为外部法律顾问为我们提供法律服务，负责开发我们的中性粒细胞的FDA监管策略。在Georgetown University Law Center毕业之前，Mounts博士在约翰霍普金斯大学公共卫生学院（Johns Hopkins University School of Public Health）任教16年，专攻分子生物学和传染病。她在苏格兰爱丁堡大学（University of Edinburgh）获得分子生物学博士学位。
Phoebe Mounts,became Cormedix Inc. Executive Vice President and General Counsel and Head of Regulatory, Compliance and Legal in May 2019 and served as Head of Technical Operations from October 2021 through January 15, 2023. Prior to her employment with Cormedix Inc. , Dr. Mounts was a partner at Morgan, Lewis & Bockius LLP, where she provided legal counsel to life sciences companies for over 20 years. As part of her work at Morgan Lewis, Dr. Mounts had been providing Cormedix Inc. legal services as outside counsel since 2013, with responsibility for developing Cormedix Inc. FDA regulatory strategies for DefenCath. Prior to graduating from Georgetown University Law Center, Dr. Mounts was on the faculty of the Johns Hopkins University School of Public Health for 16 years, specializing in molecular biology and infectious disease. She received her Ph.D. in molecular biology from the University of Edinburgh in Scotland.- Phoebe Mounts于2019年5月成为我们的执行Vice President and General Counsel兼监管，合规和法律主管。任职我们之前，她曾担任Morgan，Lewis&Bockius公司的合伙人，在那里她曾担任生命科学公司的法律顾问20年以上。作为她在Morgan Lewis工作的一部分，Mounts博士自2013年以来一直作为外部法律顾问为我们提供法律服务，负责开发我们的中性粒细胞的FDA监管策略。在Georgetown University Law Center毕业之前，Mounts博士在约翰霍普金斯大学公共卫生学院（Johns Hopkins University School of Public Health）任教16年，专攻分子生物学和传染病。她在苏格兰爱丁堡大学（University of Edinburgh）获得分子生物学博士学位。
- Phoebe Mounts,became Cormedix Inc. Executive Vice President and General Counsel and Head of Regulatory, Compliance and Legal in May 2019 and served as Head of Technical Operations from October 2021 through January 15, 2023. Prior to her employment with Cormedix Inc. , Dr. Mounts was a partner at Morgan, Lewis & Bockius LLP, where she provided legal counsel to life sciences companies for over 20 years. As part of her work at Morgan Lewis, Dr. Mounts had been providing Cormedix Inc. legal services as outside counsel since 2013, with responsibility for developing Cormedix Inc. FDA regulatory strategies for DefenCath. Prior to graduating from Georgetown University Law Center, Dr. Mounts was on the faculty of the Johns Hopkins University School of Public Health for 16 years, specializing in molecular biology and infectious disease. She received her Ph.D. in molecular biology from the University of Edinburgh in Scotland.
- Matthew David
Matthew David于2020年5月成为我们的执行Vice President和首席财务官。在加入我们之前，他最近担任Ovid Therapeutics Inc（一家后期临床生物制药公司，专注于开发罕见神经疾病的治疗方法）的战略主管，负责融资战略和投资者关系，并于2018年10月加入。在加入Ovid之前，David博士曾担任Frequency Therapeutics的战略顾问，从2017年至2019年初为融资，投资者关系和战略计划提供建议。任职Frequency公司之前，David博士曾担任投资银行家，专注于生命科学领域，包括任职Piper Jaffray公司、Thomas Weisel Partners公司、Ferghana Partners公司，最近任职Bank of America Merrill Lynch公司。作为投资银行家经验的一部分，David博士为广泛的资本筹集和战略交易提供建议。在职业生涯早期，David博士是雷曼兄弟（Lehman Brothers）股票研究团队的一部分，专注于大型制药。David博士在纽约大学医学院（NYU School of Medicine）获得医学博士学位后，作为贝斯以色列医院（Beth Israel Hospital）的外科住院医师开始了他的职业生涯。David博士在达特茅斯学院（Dartmouth College）以优异成绩获得化学文学学士学位。
Matthew David,became Cormedix Inc. Chief Financial Officer in May 2020. From October 4, 2021 through May 10, 2022, Dr. David also served as Cormedix Inc. interim Chief Executive Officer in addition to his role as Chief Financial Officer. Prior to joining Cormedix Inc. , he most recently served as Head of Strategy at Ovid Therapeutics Inc, a late-stage clinical biopharmaceutical company focused on developing treatments for rare neurological disorders, where he was responsible for financing strategy and investor relations, and joined in October 2018. Prior to Ovid, Dr. David was a Strategic Advisor to Frequency Therapeutics, advising on financing, investor relations and strategic initiatives from 2017 to early 2019. Prior to Frequency, Dr. David spent the majority of his career as an investment banker specialized in the life sciences sectors, including at Piper Jaffray, Thomas Weisel Partners, Ferghana Partners and most recently at Bank of America Merrill Lynch. As part of his experience as an investment banker, Dr. David has advised on a broad range of capital raising and strategic transactions. Earlier in his career, Dr. David was part of the equity research team at Lehman Brothers, focusing on Large Pharma. Dr. David began his career as a surgical resident at Beth Israel Hospital, after receiving an M.D. from NYU School of Medicine. Dr. David earned his Bachelor of Arts degree in Chemistry, magna cum laude, from Dartmouth College.- Matthew David于2020年5月成为我们的执行Vice President和首席财务官。在加入我们之前，他最近担任Ovid Therapeutics Inc（一家后期临床生物制药公司，专注于开发罕见神经疾病的治疗方法）的战略主管，负责融资战略和投资者关系，并于2018年10月加入。在加入Ovid之前，David博士曾担任Frequency Therapeutics的战略顾问，从2017年至2019年初为融资，投资者关系和战略计划提供建议。任职Frequency公司之前，David博士曾担任投资银行家，专注于生命科学领域，包括任职Piper Jaffray公司、Thomas Weisel Partners公司、Ferghana Partners公司，最近任职Bank of America Merrill Lynch公司。作为投资银行家经验的一部分，David博士为广泛的资本筹集和战略交易提供建议。在职业生涯早期，David博士是雷曼兄弟（Lehman Brothers）股票研究团队的一部分，专注于大型制药。David博士在纽约大学医学院（NYU School of Medicine）获得医学博士学位后，作为贝斯以色列医院（Beth Israel Hospital）的外科住院医师开始了他的职业生涯。David博士在达特茅斯学院（Dartmouth College）以优异成绩获得化学文学学士学位。
- Matthew David,became Cormedix Inc. Chief Financial Officer in May 2020. From October 4, 2021 through May 10, 2022, Dr. David also served as Cormedix Inc. interim Chief Executive Officer in addition to his role as Chief Financial Officer. Prior to joining Cormedix Inc. , he most recently served as Head of Strategy at Ovid Therapeutics Inc, a late-stage clinical biopharmaceutical company focused on developing treatments for rare neurological disorders, where he was responsible for financing strategy and investor relations, and joined in October 2018. Prior to Ovid, Dr. David was a Strategic Advisor to Frequency Therapeutics, advising on financing, investor relations and strategic initiatives from 2017 to early 2019. Prior to Frequency, Dr. David spent the majority of his career as an investment banker specialized in the life sciences sectors, including at Piper Jaffray, Thomas Weisel Partners, Ferghana Partners and most recently at Bank of America Merrill Lynch. As part of his experience as an investment banker, Dr. David has advised on a broad range of capital raising and strategic transactions. Earlier in his career, Dr. David was part of the equity research team at Lehman Brothers, focusing on Large Pharma. Dr. David began his career as a surgical resident at Beth Israel Hospital, after receiving an M.D. from NYU School of Medicine. Dr. David earned his Bachelor of Arts degree in Chemistry, magna cum laude, from Dartmouth College.
- Joseph Todisco
Joseph Todisco自2020年8月起担任专业执行副总裁兼首席商务官，此前自2018年5月起担任专业商业高级副总裁。Todisco先生于2011年加入Amneal，担任企业发展主管，并一直是执行合并的管理团队的组成部分，以及多个其他业务开发、许可和并购。除了在公司发展中的角色，Todisco先生还担任公司子公司Gemini Laboratories，LLC的管理监督责任，将其从一开始打造成一个高利润的专业制药平台，并监督Amneal’；S的所有国际商业运营（从2013年到2018年）。在加入Amneal之前，Todisco先生花了5年多的时间领导Ranbaxy’；的北美商业战略和业务发展，并在Par Pharmaceuticals担任各种领导职务。在制药行业工作之前，Todisco先生是Oppenheimer&Co.的投资银行家，也曾在Marsh&McLennan Companies的金融服务部门工作。Todisco先生拥有乔治敦大学的经济学学位和福特汉姆大学商学院的工商管理硕士学位。
Joseph Todisco,became a director of CorMedix in March 2022. Prior to joining CorMedix as Cormedix Inc. Chief Executive Officer, he was a senior executive at Amneal Pharmaceuticals, where for the past 11 years he has held various roles, most recently as Executive Vice President, Chief Commercial Officer where he was responsible for Amneal Specialty, a growing branded products business. During his tenure at Amneal, Mr. Todisco held roles overseeing corporate development and international operations, leading commercial teams in several international markets including the UK, Australia and Germany, as well as leading Amneal's merger integration with Impax Laboratories in 2018. He was previously Co-Founder and managing executive of Gemini Laboratories, a specialty pharmaceutical company focused on the sales and marketing for niche branded products in the US Market. Gemini Laboratories was established as an affiliate of Amneal Pharmaceuticals and was subsequently acquired by Amneal in 2018. Prior to joining Amneal, Mr. Todisco was Vice President, Business Development & Licensing at Ranbaxy, Inc. where he was responsible for developing and executing Ranbaxy's North American commercial business strategy. Prior to Ranbaxy, he held various roles at Par Pharmaceutical, and in his earlier career held positions at Oppenheimer & Company and Marsh & McLennan Companies. Mr. Todisco obtained his MBA in finance from Fordham Graduate School of Business and his BA in Economics from Georgetown University.- Joseph Todisco自2020年8月起担任专业执行副总裁兼首席商务官，此前自2018年5月起担任专业商业高级副总裁。Todisco先生于2011年加入Amneal，担任企业发展主管，并一直是执行合并的管理团队的组成部分，以及多个其他业务开发、许可和并购。除了在公司发展中的角色，Todisco先生还担任公司子公司Gemini Laboratories，LLC的管理监督责任，将其从一开始打造成一个高利润的专业制药平台，并监督Amneal’；S的所有国际商业运营（从2013年到2018年）。在加入Amneal之前，Todisco先生花了5年多的时间领导Ranbaxy’；的北美商业战略和业务发展，并在Par Pharmaceuticals担任各种领导职务。在制药行业工作之前，Todisco先生是Oppenheimer&Co.的投资银行家，也曾在Marsh&McLennan Companies的金融服务部门工作。Todisco先生拥有乔治敦大学的经济学学位和福特汉姆大学商学院的工商管理硕士学位。
- Joseph Todisco,became a director of CorMedix in March 2022. Prior to joining CorMedix as Cormedix Inc. Chief Executive Officer, he was a senior executive at Amneal Pharmaceuticals, where for the past 11 years he has held various roles, most recently as Executive Vice President, Chief Commercial Officer where he was responsible for Amneal Specialty, a growing branded products business. During his tenure at Amneal, Mr. Todisco held roles overseeing corporate development and international operations, leading commercial teams in several international markets including the UK, Australia and Germany, as well as leading Amneal's merger integration with Impax Laboratories in 2018. He was previously Co-Founder and managing executive of Gemini Laboratories, a specialty pharmaceutical company focused on the sales and marketing for niche branded products in the US Market. Gemini Laboratories was established as an affiliate of Amneal Pharmaceuticals and was subsequently acquired by Amneal in 2018. Prior to joining Amneal, Mr. Todisco was Vice President, Business Development & Licensing at Ranbaxy, Inc. where he was responsible for developing and executing Ranbaxy's North American commercial business strategy. Prior to Ranbaxy, he held various roles at Par Pharmaceutical, and in his earlier career held positions at Oppenheimer & Company and Marsh & McLennan Companies. Mr. Todisco obtained his MBA in finance from Fordham Graduate School of Business and his BA in Economics from Georgetown University.
- Elizabeth Hurlburt
Elizabeth Hurlburt于2018年3月成为CorMedix Inc.执行副总裁兼临床运营主管。她目前的职务是执行副总裁兼临床和医疗事务主管，自2022年5月起生效。在受雇之前，赫尔伯特自2017年11月下旬以来一直以顾问的身份为Cormedix Inc.提供临床操作方面的专业知识。在开始她的咨询职业生涯之前，她在临床运营部门担任过多个渐进式管理职位，最近在Gemphire Therapeutics担任，2015年4月至2016年10月担任临床运营高级总监，2016年10月至2018年3月担任临床运营副总裁。赫尔伯特女士在湾径学院获得了领导和组织管理学士学位，在西部州长大学获得了管理和领导硕士学位。
Elizabeth Hurlburt,became Cormedix Inc. Executive Vice President and Head of Clinical Operations in March 2018. Her current role is Executive Vice President and Head of Clinical and Medical Affairs, effective May 2022. Prior to her employment, Ms. Hurlburt had been providing Cormedix Inc. clinical operations expertise as a consultant since late November 2017. Before she began her consulting career, she held several progressive management roles in clinical operations, most recently at Gemphire Therapeutics, as a Senior Director, Clinical Operations from April 2015 to October 2016, then as Vice President, Clinical Operations from October 2016 to March 2018. Ms. Hurlburt received her B.A. in Leadership and Organizational Management from Bay Path College and a M.S. in Management and Leadership from Western Governors University.- Elizabeth Hurlburt于2018年3月成为CorMedix Inc.执行副总裁兼临床运营主管。她目前的职务是执行副总裁兼临床和医疗事务主管，自2022年5月起生效。在受雇之前，赫尔伯特自2017年11月下旬以来一直以顾问的身份为Cormedix Inc.提供临床操作方面的专业知识。在开始她的咨询职业生涯之前，她在临床运营部门担任过多个渐进式管理职位，最近在Gemphire Therapeutics担任，2015年4月至2016年10月担任临床运营高级总监，2016年10月至2018年3月担任临床运营副总裁。赫尔伯特女士在湾径学院获得了领导和组织管理学士学位，在西部州长大学获得了管理和领导硕士学位。
- Elizabeth Hurlburt,became Cormedix Inc. Executive Vice President and Head of Clinical Operations in March 2018. Her current role is Executive Vice President and Head of Clinical and Medical Affairs, effective May 2022. Prior to her employment, Ms. Hurlburt had been providing Cormedix Inc. clinical operations expertise as a consultant since late November 2017. Before she began her consulting career, she held several progressive management roles in clinical operations, most recently at Gemphire Therapeutics, as a Senior Director, Clinical Operations from April 2015 to October 2016, then as Vice President, Clinical Operations from October 2016 to March 2018. Ms. Hurlburt received her B.A. in Leadership and Organizational Management from Bay Path College and a M.S. in Management and Leadership from Western Governors University.
- Erin Mistry
Erin Mistry于2020年3月成为CorMedix Inc.付款人战略、政府事务和贸易高级副总裁。她目前的职务是执行副总裁兼首席商务官，自2023年1月起生效。在加入CorMedix之前，Erin曾在Intarcia Therapeutics担任市场准入副总裁，并在Syneos Health担任全球价值和准入业务高级董事总经理。在她的职业生涯中，Erin与新兴、中型和大型生物制药公司合作，专注于定价、准入和报销。她目前在华盛顿特区的孵化联盟和抗微生物工作组担任董事。Erin拥有北卡罗来纳州立大学工业工程（医疗保健）学士学位和生物力学工程硕士学位。
Erin Mistry,became Cormedix Inc. Senior Vice President of Payer Strategy, Government Affairs and Trade in March 2020. Her current role is Executive Vice President and Chief Commercial Officer, effective January 2023. Prior to joining CorMedix, Erin held roles as VP market access at Intarcia therapeutics as well as Senior Managing Director of the global Value and Access practice at Syneos Health. During her career, Erin has worked with emerging, mid-size, and large biopharma companies with a focus on pricing, access and reimbursement. She currently serves on the boards of Incubate Coalition and the AntiMicrobial Working Group, both in Washington, DC. Erin holds a B.S. in Industrial Engineering (healthcare) and an M.S. in Biomechanical Engineering from North Carolina State University.- Erin Mistry于2020年3月成为CorMedix Inc.付款人战略、政府事务和贸易高级副总裁。她目前的职务是执行副总裁兼首席商务官，自2023年1月起生效。在加入CorMedix之前，Erin曾在Intarcia Therapeutics担任市场准入副总裁，并在Syneos Health担任全球价值和准入业务高级董事总经理。在她的职业生涯中，Erin与新兴、中型和大型生物制药公司合作，专注于定价、准入和报销。她目前在华盛顿特区的孵化联盟和抗微生物工作组担任董事。Erin拥有北卡罗来纳州立大学工业工程（医疗保健）学士学位和生物力学工程硕士学位。
- Erin Mistry,became Cormedix Inc. Senior Vice President of Payer Strategy, Government Affairs and Trade in March 2020. Her current role is Executive Vice President and Chief Commercial Officer, effective January 2023. Prior to joining CorMedix, Erin held roles as VP market access at Intarcia therapeutics as well as Senior Managing Director of the global Value and Access practice at Syneos Health. During her career, Erin has worked with emerging, mid-size, and large biopharma companies with a focus on pricing, access and reimbursement. She currently serves on the boards of Incubate Coalition and the AntiMicrobial Working Group, both in Washington, DC. Erin holds a B.S. in Industrial Engineering (healthcare) and an M.S. in Biomechanical Engineering from North Carolina State University.